Literature DB >> 8010267

Acetazolamide challenge for three-dimensional time-of-flight MR angiography of the brain.

K Mandai1, K Sueyoshi, R Fukunaga, M Nukada, F Ohtani, Y Araki, I Tsukaguchi, H Abe.   

Abstract

PURPOSE: We compared three-dimensional time-of-flight MR angiograms obtained before and after acetazolamide administration to evaluate whether use of this drug could improve visualization of small peripheral intracranial arteries and atherosclerotic stenosis.
METHODS: For evaluation of small peripheral arteries, 10 patients with clinical diagnosis of ischemic cerebrovascular disease and 10 healthy volunteers were investigated, and for evaluation of stenosis, another 6 patients were investigated. Vascular images were obtained by three-dimensional time-of-flight MR angiography. After a baseline scan, 17 mg/kg acetazolamide was injected intravenously and the second scan was performed 20 minutes later.
RESULTS: Several small peripheral arteries that had not been seen on the baseline images were visible on the acetazolamide images without any augmentation of the background signals. Stenotic lesions in the main trunks of the major cerebral arteries were detected more clearly on acetazolamide images.
CONCLUSIONS: Acetazolamide improves visualization of small peripheral intracranial arteries and sensitivity in detecting atherosclerotic stenosis in the main trunk of major cerebral artery by three-dimensional time-of-flight MR angiography without changing MR apparatus and software.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8010267      PMCID: PMC8334210     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  1 in total

1.  Prominent laterality of the posterior cerebral artery at three-dimensional time-of-flight MR angiography in M1-segment middle cerebral artery occlusion.

Authors:  Akihiro Uemura; Toshihiro O'uchi; Yoichi Kikuchi; Naobumi Yashiro; Nobumaro Ihara; Kazufusa Shoji
Journal:  AJNR Am J Neuroradiol       Date:  2004-01       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.